Olema Oncology
Ashley Abraham has extensive experience in clinical research, currently serving as a Senior Clinical Research Associate at ReCode Therapeutics and Olema Oncology since 2023 and 2021, respectively. Prior experience includes roles such as Clinical Research Associate II at Calithera Biosciences from 2017 to 2021, where responsibilities encompassed leading studies, managing timelines, vendor selection, and quality oversight. Previous positions also include Clinical Research Associate at Pharmacyclics and Clinical Research Assistant at ProTrials Research, demonstrating a solid foundation in clinical operations, data management, and regulatory compliance. Ashley holds a Bachelor's degree in Biology and a minor in Sociology from UC San Diego.
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.